|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
|
AP3329A
(en)
|
2009-07-13 |
2015-06-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
|
SMT201700583T1
(it)
|
2009-09-28 |
2018-01-11 |
Intarcia Therapeutics Inc |
Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
|
|
EP2512518A1
(en)
*
|
2009-12-16 |
2012-10-24 |
Novo Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
|
EP2637698B1
(en)
|
2010-11-09 |
2022-04-20 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
MX377589B
(es)
|
2010-12-16 |
2025-03-10 |
Novo Nordisk As |
Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
|
|
US20120208755A1
(en)
*
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
RU2602601C2
(ru)
|
2011-04-12 |
2016-11-20 |
Ново Нордиск А/С |
Дважды ацилированные производные glp-1
|
|
KR20140053991A
(ko)
|
2011-07-18 |
2014-05-08 |
아츠 바이올로직스 에이/에스 |
장기간 작용하는 황체 형성 호르몬 (ｌｈ) 화합물
|
|
EP2753642B8
(en)
*
|
2011-09-06 |
2017-12-13 |
Novo Nordisk A/S |
Glp-1 derivatives
|
|
JP6046161B2
(ja)
|
2011-12-29 |
2016-12-14 |
ノヴォ ノルディスク アー／エス |
非タンパク質新生アミノ酸を含むジペプチド
|
|
ES2810153T3
(es)
*
|
2012-03-01 |
2021-03-08 |
Novo Nordisk As |
Profármacos de GLP-1
|
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
|
CN104203266B
(zh)
|
2012-03-22 |
2017-12-26 |
诺和诺德股份有限公司 |
Glp‑1肽组合物及其制备
|
|
JP6228187B2
(ja)
|
2012-05-03 |
2017-11-08 |
ジーランド ファーマ アクティーゼルスカブ |
Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
|
|
JP6250034B2
(ja)
*
|
2012-05-08 |
2017-12-20 |
ノヴォ ノルディスク アー／エス |
二重アシル化されたｇｌｐ−１誘導体
|
|
ES2629735T3
(es)
*
|
2012-05-08 |
2017-08-14 |
Novo Nordisk A/S |
Derivados de GLP-1 doblemente acilados
|
|
WO2013170636A1
(zh)
|
2012-05-18 |
2013-11-21 |
爱德迪安（北京）生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
|
JP6517690B2
(ja)
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー／エス |
ペプチド及び送達剤を含む錠剤製剤
|
|
HRP20251088T1
(hr)
|
2012-07-01 |
2025-11-07 |
Novo Nordisk A/S |
Upotreba dugodjelujućih peptida glp‑1
|
|
AU2013295035B2
(en)
|
2012-07-23 |
2017-08-03 |
Zealand Pharma A/S |
Glucagon analogues
|
|
FR2994848B1
(fr)
|
2012-08-30 |
2014-08-22 |
Univ Paris Curie |
Traitement de l'arthrose par les hormones incretines ou leurs analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
EP2915817B1
(en)
|
2012-10-31 |
2018-06-20 |
Hybio Pharmaceutical Co., Ltd. |
Method for preparing exenatide
|
|
HK1211232A1
(en)
|
2012-12-21 |
2016-05-20 |
Sanofi |
Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
|
|
JP6672140B2
(ja)
|
2013-05-02 |
2020-03-25 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１化合物の経口投薬
|
|
KR20160021183A
(ko)
*
|
2013-06-20 |
2016-02-24 |
노보 노르디스크 에이/에스 |
Glp-1 유도체 및 그것의 용도
|
|
WO2015000942A1
(en)
|
2013-07-04 |
2015-01-08 |
Novo Nordisk A/S |
Derivatives of glp-1 like peptides, and uses thereof
|
|
US10266577B2
(en)
|
2013-08-15 |
2019-04-23 |
Novo Nordisk A/S |
GLP-1 derivatives, and uses thereof
|
|
CN105792851B
(zh)
|
2013-09-13 |
2023-10-10 |
斯克利普斯研究所 |
修饰的治疗剂及其组合物
|
|
WO2015055801A1
(en)
|
2013-10-17 |
2015-04-23 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AU2014345570B2
(en)
|
2013-11-06 |
2019-01-24 |
Zealand Pharma A/S |
Glucagon-GLP-1-GIP triple agonist compounds
|
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
|
CN112043835B
(zh)
|
2013-12-06 |
2022-10-21 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／ｇｉｐ受體促效劑
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
AU2014364589B2
(en)
|
2013-12-18 |
2020-02-27 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
US10689429B2
(en)
*
|
2014-04-07 |
2020-06-23 |
Novo Nordisk A/S |
Double-acylated GLP-1 compounds
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
*
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
AU2015274482B2
(en)
|
2014-06-12 |
2018-11-08 |
Ucb Holdings, Inc. |
Modulation of complement activity
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
US10253078B2
(en)
|
2014-10-29 |
2019-04-09 |
Zealand Pharma A/S |
GIP agonist compounds and methods
|
|
JP6730278B2
(ja)
|
2014-11-27 |
2020-07-29 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
WO2016097108A1
(en)
|
2014-12-17 |
2016-06-23 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
EP3250230B9
(en)
|
2015-01-28 |
2022-02-23 |
RA Pharmaceuticals, Inc. |
Modulators of complement activity
|
|
CN107205949A
(zh)
*
|
2015-01-29 |
2017-09-26 |
诺和诺德股份有限公司 |
包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
|
|
US10265384B2
(en)
*
|
2015-01-29 |
2019-04-23 |
Novo Nordisk A/S |
Tablets comprising GLP-1 agonist and enteric coating
|
|
US10336802B2
(en)
|
2015-04-16 |
2019-07-02 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
|
AU2016270373A1
(en)
|
2015-06-05 |
2018-01-04 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
EP3319968A1
(en)
|
2015-07-06 |
2018-05-16 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
LT3319959T
(lt)
|
2015-07-06 |
2021-12-27 |
Alkermes, Inc. |
Histono deacetilazės hetero-halogeno inhibitoriai
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
CN106496322A
(zh)
*
|
2015-09-07 |
2017-03-15 |
江苏恒瑞医药股份有限公司 |
人胰岛素或其类似物的酰化衍生物的制备方法
|
|
EP3368556B1
(en)
*
|
2015-10-28 |
2024-04-10 |
Tufts University |
Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
|
|
ES2941640T3
(es)
|
2015-12-16 |
2023-05-24 |
Ra Pharmaceuticals Inc |
Moduladores de la actividad del complemento
|
|
GB2551945B
(en)
*
|
2015-12-18 |
2021-09-08 |
Heptares Therapeutics Ltd |
Novel GLP-1 receptor agonist peptides
|
|
WO2017149070A1
(en)
|
2016-03-03 |
2017-09-08 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
RU2760007C2
(ru)
|
2016-05-16 |
2021-11-22 |
Интарсия Терапьютикс, Инк. |
Полипептиды, селективные к рецепторам глюкагона, и способы их применения
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
CN107561168A
(zh)
*
|
2016-06-30 |
2018-01-09 |
山东新时代药业有限公司 |
一种聚乙二醇化促胰岛素分泌肽类似物的分析检测方法
|
|
MA46780A
(fr)
|
2016-11-07 |
2019-09-11 |
Novo Nordisk As |
Esters à dchbs actif de composés peg et leur utilisation
|
|
WO2018106646A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Aminotriazoles for the treatment of demyelinating diseases
|
|
WO2018106643A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic azoles for the treatment of demyelinating diseases
|
|
WO2018106641A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles for the treatment of demyelinating diseases
|
|
MX2019006527A
(es)
|
2016-12-07 |
2019-08-01 |
Ra Pharmaceuticals Inc |
Moduladores de la actividad del complemento.
|
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
|
RS62959B1
(sr)
|
2017-01-11 |
2022-03-31 |
Alkermes Inc |
Biciklični inhibitori histon-deacetilaze
|
|
FR3061715B1
(fr)
|
2017-01-12 |
2021-07-30 |
Institut National Univ Jean Francois Champollion |
Peptide immunomodulateur
|
|
CN110545838A
(zh)
*
|
2017-03-08 |
2019-12-06 |
因塔西亚制药公司 |
用于从药物递送装置施用致恶心化合物的设备和方法
|
|
AR112015A1
(es)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
Composiciones sólidas para administración oral
|
|
US11225475B2
(en)
|
2017-08-07 |
2022-01-18 |
Alkermes, Inc. |
Substituted pyridines as inhibitors of histone deacetylase
|
|
HRP20240485T1
(hr)
|
2017-08-24 |
2024-07-05 |
Novo Nordisk A/S |
Pripravci glp-1 i njihova upotreba
|
|
JP6984923B2
(ja)
*
|
2017-09-19 |
2021-12-22 |
イミュンワーク インク.Immunwork Inc. |
アルブミンとの強化された結合親和性を有する医薬構築物
|
|
JP7148605B2
(ja)
|
2017-10-12 |
2022-10-05 |
ノヴォ ノルディスク アー／エス |
医学療法におけるセマグルチド
|
|
PL3746111T3
(pl)
|
2018-02-02 |
2024-01-15 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
|
|
RS63523B1
(sr)
|
2018-04-05 |
2022-09-30 |
Sun Pharmaceutical Ind Ltd |
Novi glp-1 analozi
|
|
KR102379958B1
(ko)
*
|
2018-05-04 |
2022-04-01 |
노보 노르디스크 에이/에스 |
Gip 유도체 및 이의 용도
|
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
|
CN109134257A
(zh)
*
|
2018-10-08 |
2019-01-04 |
扬州工业职业技术学院 |
一种两步法制备高纯度十二烷基二酸单叔丁酯的方法
|
|
CN109111361A
(zh)
*
|
2018-10-08 |
2019-01-01 |
扬州工业职业技术学院 |
一种一步法高效制备十二烷基二酸单叔丁酯的方法
|
|
WO2020118843A1
(zh)
*
|
2018-12-12 |
2020-06-18 |
四川利通科创生物医药科技有限公司 |
一种glp-1突变体及其制备方法和用途
|
|
US20220072493A1
(en)
|
2019-01-24 |
2022-03-10 |
Novo Nordisk A/S |
Roller compactor and method of dry granulation using a roller compactor
|
|
EP3930757A1
(en)
|
2019-03-01 |
2022-01-05 |
President And Fellows Of Harvard College |
Methods and compositions for protein delivery
|
|
US20220257767A1
(en)
|
2019-04-03 |
2022-08-18 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
CN113966224A
(zh)
|
2019-06-04 |
2022-01-21 |
Ra制药公司 |
采用补体抑制剂的炎性疾病治疗
|
|
WO2021070202A1
(en)
*
|
2019-10-09 |
2021-04-15 |
Prasad Alaparthi Lakshmi |
A method for preparing glp-1 analogue by solid-phase peptide synthesis
|
|
CA3154744A1
(en)
|
2019-11-06 |
2021-05-14 |
Sarah FRIEDRICH |
Glp-1 receptor agonists in dementia
|
|
CN114641276A
(zh)
|
2019-11-07 |
2022-06-17 |
诺和诺德股份有限公司 |
包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
|
|
WO2021102084A1
(en)
|
2019-11-22 |
2021-05-27 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
AU2020397917A1
(en)
|
2019-12-04 |
2022-06-23 |
The Scripps Research Institute |
GLP2 receptor agonists and methods of use
|
|
CN115260313B
(zh)
|
2019-12-31 |
2023-07-18 |
北京质肽生物医药科技有限公司 |
Glp-1和gdf15的融合蛋白以及其缀合物
|
|
PE20230819A1
(es)
|
2020-02-18 |
2023-05-19 |
Novo Nordisk As |
Composiciones y usos de glp-1
|
|
GB202003762D0
(en)
*
|
2020-03-16 |
2020-04-29 |
Heptares Therapeutics Ltd |
GLP receptor agonists
|
|
EP4142695B1
(en)
|
2020-04-29 |
2025-11-05 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and histidine
|
|
WO2021239082A1
(zh)
*
|
2020-05-29 |
2021-12-02 |
北京拓界生物医药科技有限公司 |
Glp-1和gip受体双重激动剂化合物及其应用
|
|
WO2022018748A1
(en)
*
|
2020-07-18 |
2022-01-27 |
Dr. Reddy's Laboratories Limited |
Improved purification process of semaglutide
|
|
MX2023000303A
(es)
|
2020-07-22 |
2023-02-09 |
Novo Nordisk As |
Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
|
|
CN114729060B
(zh)
*
|
2020-09-30 |
2022-11-25 |
北京质肽生物医药科技有限公司 |
多肽缀合物和使用方法
|
|
MY206918A
(en)
|
2020-11-06 |
2025-01-17 |
Novo Nordisk As |
Glp-1 prodrugs and uses hereof
|
|
TWI850611B
(zh)
*
|
2020-12-18 |
2024-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1及澱粉素受體之共促效劑
|
|
CN114685644A
(zh)
*
|
2020-12-29 |
2022-07-01 |
苏州康宁杰瑞生物科技有限公司 |
一种人glp-1多肽变体及其应用
|
|
WO2022175384A1
(en)
*
|
2021-02-17 |
2022-08-25 |
Fundación Universidad Católica De Valencia San Vicente Mártir |
Small-molecule agents with antiviral activity against rna viruses
|
|
MX2023014771A
(es)
|
2021-06-09 |
2024-03-19 |
Scripps Research Inst |
Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
|
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
|
CN118382429A
(zh)
|
2021-10-08 |
2024-07-23 |
哈佛大学校长及研究员协会 |
用于药物递送的离子液体
|
|
EP4429704A4
(en)
|
2021-11-10 |
2025-11-05 |
I2O Therapeutics Inc |
IONIC LIQUID COMPOSITIONS
|
|
CN116650424A
(zh)
*
|
2022-01-06 |
2023-08-29 |
鸿绪生物医药科技（北京）有限公司 |
新型多肽制剂及其治疗用途
|
|
TW202330584A
(zh)
|
2022-01-20 |
2023-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
前藥及其用途
|
|
EP4323413A4
(en)
|
2022-03-30 |
2025-10-15 |
Beijing Ql Biopharmaceutical Co Ltd |
LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
|
|
JP2025517672A
(ja)
|
2022-05-10 |
2025-06-10 |
ノヴォ ノルディスク アー／エス |
プロドラッグおよびその使用
|
|
CA3260606A1
(en)
|
2022-06-30 |
2024-01-04 |
Sanofi |
NEW PEPTIDES FOR USE AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS
|
|
CN116514952B
(zh)
*
|
2022-10-13 |
2024-02-02 |
江苏师范大学 |
一类glp-1类似物及其应用
|
|
TW202421645A
(zh)
|
2022-11-25 |
2024-06-01 |
丹麥商諾佛 儂迪克股份有限公司 |
如ｇｌｐ—１之肽治療劑的口服投與
|
|
JP2026502943A
(ja)
|
2022-12-30 |
2026-01-27 |
アルギファルマ エーエス |
経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
|
|
WO2024245946A1
(en)
*
|
2023-05-26 |
2024-12-05 |
Gubra A/S |
Secretin-derived glp1r selective agonists
|
|
CN120676965A
(zh)
*
|
2023-11-07 |
2025-09-19 |
深圳信立泰药业股份有限公司 |
多重受体共激动剂化合物及其制备方法与应用
|
|
WO2026072611A1
(en)
*
|
2024-09-24 |
2026-04-02 |
Eli Lilly And Company |
Tirzepatide binding molecules, and uses thereof
|